Datum objave: 16.06.2011
Kategorija: Aktualno na Univerzi
Allinky Biopharma
Contact Person
VEGA, MIguel (Mr.)
Allinky Biopharma
Contact
Telephone: +34-620-947503
Collaboration
Project Proposal
Title: Targeting molecular pathophysiology of type II diabetes: preclinical development, animal proof of concept and safety profile evaluation of allosteric MAP Kinase modulators as insulin sensitizers (GLYKONTROL)
Type Details: Targeting molecular pathophysiology of type II diabetes: preclinical development, animal proof of concept and safety profile evaluation of allosteric MAP Kinase modulators as insulin sensitizers (GLYKONTROL)
Programme (Collaboration EU R&D): FP7-HEALTH
Expiry Date: 2012-06-02
Target Partner
Expertise: Cell assays to evaluate insulin sensitizers
Animal proof of concept for insulin sensitizers and glycemic index modulators
Crystallography expertise to elucidate ligand-target binding
Formulation and medicinal chemistry to improve pharmacokinetic properties of chemical compounds
ADME evaluation in animals
Toxicology evaluation in animals
Organisation Details
Allinky BiopharmaName: Allinky Biopharma
Region: COMUNIDAD DE MADRID
SPAIN
Type: SME (Small or Medium sized Enterprise)
Number of Employees: < 10
RCN: 87176
Quality Validation Date: 2011-06-02
Update Date: 2011-06-06